Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2024-03-25 Sale | 2024-03-27 5:03 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $17.56 | $210,661 | 1,525,137 (Indirect Direct) | View |
2024-03-20 Sale | 2024-03-22 7:46 pm | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 13,278 | $19.16 | $254,462 | 41,912 (Direct) | View |
2024-03-19 Sale | 2024-03-21 6:41 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $14.5 | $18,419 | 210,093 (Indirect Direct) | View |
2024-03-06 Sale | 2024-03-08 7:52 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 4,875 | $15.64 | $76,239 | 401,499 (Indirect Direct) | View |
2024-02-29 Sale | 2024-03-04 5:55 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $16.42 | $197,006 | 1,389,585 (Indirect Direct) | View |
2024-02-27 Sale | 2024-02-29 5:27 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $16.97 | $55,163 | 242,620 (Direct) | View |
2024-02-26 Sale | 2024-02-28 5:14 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $16.89 | $202,653 | 1,537,137 (Indirect Direct) | View |
2024-02-15 Sale | 2024-02-20 7:41 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $17.42 | $22,117 | 211,363 (Indirect Direct) | View |
2024-02-14 Sale | 2024-02-16 4:15 pm | Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH Schwab Andrew J. 10% Owner | 825,000 | $14.9 | $12,292,500 | 635,341 (Indirect) | View |
2024-02-06 Sale | 2024-02-08 8:47 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 4,875 | $15.11 | $73,658 | 406,374 (Indirect Direct) | View |
2024-01-31 Sale | 2024-02-02 4:29 pm | Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH Schwab Andrew J. 10% Owner | 500,000 | $15 | $7,500,000 | 771,983 (Indirect) | View |
2024-01-30 Sale | 2024-02-01 8:10 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $16.41 | $20,840 | 212,633 (Indirect Direct) | View |
2024-01-29 Sale | 2024-01-31 9:22 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $15.85 | $190,256 | 1,401,585 (Indirect Direct) | View |
2024-01-29 Sale | 2024-01-31 9:20 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $15.81 | $51,388 | 245,870 (Direct) | View |
2024-01-25 Sale | 2024-01-29 8:01 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO | 12,000 | $15.69 | $188,229 | 1,549,137 (Indirect Direct) | View |
2024-01-22 Sale | 2024-01-24 6:38 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer | 4,875 | $15.13 | $73,783 | 411,249 (Indirect Direct) | View |
2023-12-29 Sale | 2024-01-03 7:01 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 12,000 | $14.28 | $171,381 | 1,413,585 (Indirect Direct) | View |
2023-12-28 Sale | 2024-01-02 8:00 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer | 13,540 | $15.02 | $203,348 | 416,124 (Indirect Direct) | View |
2023-12-28 Sale | 2024-01-02 7:59 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 11,870 | $15.02 | $178,327 | 766,146 (Direct) | View |
2023-12-26 Sale | 2023-12-28 4:29 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO | 12,000 | $14.64 | $175,709 | 1,561,137 (Indirect Direct) | View |
2023-12-22 Sale | 2023-12-27 5:28 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer | 1,085 | $15.03 | $16,306 | 429,664 (Indirect Direct) | View |
2023-12-22 Sale | 2023-12-27 5:26 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 1,130 | $15.07 | $17,025 | 522,080 (Direct) | View |
2023-12-21 Sale | 2023-12-26 7:32 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 6,566 | $13.07 | $85,790 | 1,740,681 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-03-25 Exercise | 2024-03-27 5:03 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $1.12 | 1,525,137 (Direct) | View |
2024-03-25 Exercise | 2024-03-27 5:03 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $0 | 1,525,137 (Direct) | View |
2024-03-20 Exercise | 2024-03-22 7:46 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 13,278 | $5.52 | 41,912 (Direct) | View |
2024-03-20 Exercise | 2024-03-22 7:46 pm | N/A 2032-01-27 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 13,278 | $0 | 41,912 (Direct) | View |
2024-02-29 Exercise | 2024-03-04 5:55 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $1.12 | 1,389,585 (Direct) | View |
2024-02-29 Exercise | 2024-03-04 5:55 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $0 | 1,389,585 (Direct) | View |
2024-02-27 Exercise | 2024-02-29 5:27 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 242,620 (Direct) | View |
2024-02-27 Exercise | 2024-02-29 5:27 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 242,620 (Direct) | View |
2024-02-26 Exercise | 2024-02-28 5:14 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $1.12 | 1,537,137 (Direct) | View |
2024-02-26 Exercise | 2024-02-28 5:14 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $0 | 1,537,137 (Direct) | View |
2024-02-13 Option Award(A) | 2024-02-20 7:35 pm | N/A 2034-02-13 | Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director | 23,364 | $0 | 23,364 (Direct) | View |
2024-02-13 Option Award(A) | 2024-02-20 7:32 pm | N/A 2034-02-13 | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 29,205 | $0 | 29,205 (Direct) | View |
2024-02-13 Option Award(A) | 2024-02-20 7:30 pm | N/A 2034-02-13 | Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner | 23,364 | $0 | 23,364 (Direct) | View |
2024-02-13 Option Award(A) | 2024-02-20 7:27 pm | N/A 2034-02-13 | Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director | 23,364 | $0 | 23,364 (Direct) | View |
2024-02-13 Option Award(A) | 2024-02-20 7:26 pm | N/A 2034-02-13 | Enliven Therapeutics Inc. | ELVN | Bauer Jake Director | 23,364 | $0 | 23,364 (Direct) | View |
2024-02-13 Option Award(A) | 2024-02-20 7:24 pm | N/A 2034-02-13 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 23,364 | $0 | 23,364 (Direct) | View |
2024-02-13 Option Award | 2024-02-15 9:04 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director | 16,835 | $0 | 16,835 (Direct) | View |
2024-02-13 Option Award | 2024-02-15 9:02 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 185,000 | $0 | 185,000 (Direct) | View |
2024-02-13 Option Award | 2024-02-15 9:00 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 185,000 | $0 | 185,000 (Direct) | View |
2024-02-13 Option Award | 2024-02-15 8:56 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 410,000 | $0 | 410,000 (Direct) | View |
2024-02-13 Option Award | 2024-02-15 8:54 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 185,000 | $0 | 185,000 (Direct) | View |
2024-02-13 Option Award | 2024-02-15 8:52 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 21,043 | $0 | 21,043 (Direct) | View |
2024-02-13 Option Award | 2024-02-15 8:50 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner | 16,835 | $0 | 16,835 (Direct) | View |
2024-02-13 Option Award | 2024-02-15 8:48 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director | 16,835 | $0 | 16,835 (Direct) | View |
2024-02-13 Option Award | 2024-02-15 8:46 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 185,000 | $0 | 185,000 (Direct) | View |
2024-02-13 Option Award | 2024-02-15 8:44 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Bauer Jake Director | 16,835 | $0 | 16,835 (Direct) | View |
2024-02-13 Option Award | 2024-02-15 8:41 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 16,835 | $0 | 16,835 (Direct) | View |
2024-01-29 Exercise | 2024-01-31 9:22 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $1.12 | 1,401,585 (Direct) | View |
2024-01-29 Exercise | 2024-01-31 9:22 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $0 | 1,401,585 (Direct) | View |
2024-01-29 Exercise | 2024-01-31 9:20 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 245,870 (Direct) | View |
2024-01-29 Exercise | 2024-01-31 9:20 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 245,870 (Direct) | View |
2024-01-25 Exercise | 2024-01-29 8:01 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO | 12,000 | $1.12 | 1,549,137 (Direct) | View |
2024-01-25 Exercise | 2024-01-29 8:01 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO | 12,000 | $0 | 1,549,137 (Direct) | View |
2023-12-29 Exercise | 2024-01-03 7:01 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 12,000 | $1.12 | 1,413,585 (Direct) | View |
2023-12-29 Exercise | 2024-01-03 7:01 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 12,000 | $0 | 1,413,585 (Direct) | View |
2023-12-28 Exercise | 2024-01-02 7:59 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 11,870 | $0 | 766,146 (Direct) | View |
2023-12-28 Exercise | 2024-01-02 7:59 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 11,870 | $2.48 | 766,146 (Direct) | View |
2023-12-26 Exercise | 2023-12-28 4:29 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO | 12,000 | $1.12 | 1,561,137 (Direct) | View |
2023-12-26 Exercise | 2023-12-28 4:29 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO | 12,000 | $0 | 1,561,137 (Direct) | View |
2023-12-22 Exercise | 2023-12-27 5:26 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 1,130 | $0 | 522,080 (Direct) | View |
2023-12-22 Exercise | 2023-12-27 5:26 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 1,130 | $2.48 | 522,080 (Direct) | View |
2023-12-21 Exercise | 2023-12-26 7:32 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 6,566 | $1.12 | 1,740,681 (Direct) | View |
2023-12-21 Exercise | 2023-12-26 7:32 pm | N/A 2030-06-15 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer | 6,566 | $0 | 1,740,681 (Direct) | View |